Altered bioavailability of drugs in the eye due to drug-protein interaction.
D000818:Animals; D001082:Aqueous Humor / Q000378:metabolism; D001702:Biopharmaceutics; D003315:Cornea / Q000378:metabolism; D003956:Dialysis; D004347:Drug Interactions; D005136:Eye Proteins / Q000378:metabolism*; D007700:Kinetics; D008297:Male; D008775:Methylprednisolone / Q000378:metabolism; D008938:Mitosis / Q000187:drug effects; D009281:Naphthalenes / Q000378:metabolism; D004364:Pharmaceutical Preparations / Q000378:metabolism*; D010862:Pilocarpine / Q000378:metabolism; D011485:Protein Binding; D011817:Rabbits; D012709:Serum Albumin / Q000378:metabolism; D012996:Solutions / Q000378:metabolism; D013444:Sulfisoxazole / Q000378:metabolism; D013449:Sulfonamides / Q000378:metabolism; D013666:Tears; D013997:Time Factors; D014316:Tritium
D005136:Eye Proteins; D009281:Naphthalenes; D004364:Pharmaceutical Preparations; D012709:Serum Albumin; D012996:Solutions; D013449:Sulfonamides; D010862:Pilocarpine; D014316:Tritium; D013444:Sulfisoxazole; D008775:Methylprednisolone